

Sampa Santra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6604773/publications.pdf>

Version: 2024-02-01

50
papers

4,751
citations

159585

30
h-index

189892

50
g-index

52
all docs

52
docs citations

52
times ranked

6066
citing authors

#	ARTICLE	IF	CITATIONS
1	Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys by Cytokine-Augmented DNA Vaccination. <i>Science</i> , 2000, 290, 486-492.	12.6	876
2	Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. <i>Nature</i> , 2017, 543, 248-251.	27.8	699
3	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. <i>Immunity</i> , 2013, 38, 176-186.	14.3	374
4	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. <i>Cell Host and Microbe</i> , 2021, 29, 23-31.e4.	11.0	308
5	Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. <i>Nature Medicine</i> , 2010, 16, 324-328.	30.7	211
6	Reduction of Simian-Human Immunodeficiency Virus 89.6P Viremia in Rhesus Monkeys by Recombinant Modified Vaccinia Virus Ankara Vaccination. <i>Journal of Virology</i> , 2001, 75, 5151-5158.	3.4	186
7	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3413-22.	7.1	170
8	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. <i>PLoS Pathogens</i> , 2015, 11, e1005042.	4.7	145
9	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. <i>Nature Communications</i> , 2017, 8, 15711.	12.8	137
10	Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates. <i>Journal of Virology</i> , 2005, 79, 6516-6522.	3.4	136
11	Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion. <i>Journal of Virology</i> , 2013, 87, 1554-1568.	3.4	97
12	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. <i>Cell Reports</i> , 2017, 21, 3681-3690.	6.4	97
13	Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. <i>Science Translational Medicine</i> , 2016, 8, 336ra62.	12.4	86
14	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	81
15	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. <i>Nature Communications</i> , 2017, 8, 1732.	12.8	76
16	A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10489-10494.	7.1	75
17	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. <i>Cell Reports</i> , 2017, 18, 2175-2188.	6.4	69
18	Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved. <i>Immunity</i> , 2014, 41, 909-918.	14.3	65

#	ARTICLE	IF	CITATIONS
19	Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 11088-11093.	7.1	58
20	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. <i>EBioMedicine</i> , 2016, 14, 97-111.	6.1	47
21	Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. <i>Virology</i> , 2012, 428, 121-127.	2.4	46
22	A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. <i>Nature Communications</i> , 2018, 9, 2363.	12.8	46
23	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. <i>Npj Vaccines</i> , 2021, 6, 50.	6.0	46
24	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. <i>Cell Reports</i> , 2016, 14, 43-54.	6.4	45
25	Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. <i>Vaccine</i> , 2009, 27, 5837-5845.	3.8	44
26	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. <i>Molecular Therapy</i> , 2016, 24, 2021-2032.	8.2	41
27	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. <i>Journal of Virology</i> , 2015, 89, 6462-6480.	3.4	40
28	Recombinant Canarypox Vaccine-Elicited CTL Specific for Dominant and Subdominant Simian Immunodeficiency Virus Epitopes in Rhesus Monkeys. <i>Journal of Immunology</i> , 2002, 168, 1847-1853.	0.8	38
29	Heterologous Prime/Boost Immunization of Rhesus Monkeys by Using Diverse Poxvirus Vectors. <i>Journal of Virology</i> , 2007, 81, 8563-8570.	3.4	38
30	Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. <i>Journal of Virology</i> , 2016, 90, 5031-5046.	3.4	38
31	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. <i>EBioMedicine</i> , 2016, 12, 196-207.	6.1	34
32	B7 co-stimulatory requirements differ for induction of immune responses by DNA, protein and recombinant pox virus vaccination. <i>European Journal of Immunology</i> , 2000, 30, 2650-2659.	2.9	28
33	Immune checkpoint modulation enhances HIV-1 antibody induction. <i>Nature Communications</i> , 2020, 11, 948.	12.8	27
34	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. <i>Communications Biology</i> , 2018, 1, 134.	4.4	26
35	Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. <i>Virology</i> , 2015, 475, 37-45.	2.4	25
36	Prior Vaccination Increases the Epitopic Breadth of the Cytotoxic T-Lymphocyte Response That Evolves in Rhesus Monkeys following a Simian-Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2002, 76, 6376-6381.	3.4	21

#	ARTICLE	IF	CITATIONS
37	Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. <i>Cell Reports</i> , 2020, 30, 1553-1569.e6.	6.4	21
38	The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. <i>Nature Immunology</i> , 2021, 22, 1294-1305.	14.5	20
39	Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw034.	0.9	15
40	Strong T _H 1-biased CD4 T cell responses are associated with diminished SIV vaccine efficacy. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	14
41	Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition. <i>PLoS Pathogens</i> , 2020, 16, e1008377.	4.7	14
42	Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques. <i>Npj Vaccines</i> , 2020, 5, 36.	6.0	12
43	Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs. <i>Npj Vaccines</i> , 2020, 5, 107.	6.0	11
44	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. <i>Journal of Virology</i> , 2018, 92, .	3.4	10
45	Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. <i>JCI Insight</i> , 2016, 1, e88522.	5.0	10
46	HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. <i>Journal of Immunology</i> , 2016, 197, 4663-4673.	0.8	6
47	Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses. <i>Journal of Virology</i> , 2021, 95, .	3.4	6
48	Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center. <i>Npj Vaccines</i> , 2021, 6, 15.	6.0	5
49	Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection. <i>Vaccine</i> , 2014, 32, 3995-4000.	3.8	4
50	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. <i>PLoS Pathogens</i> , 2021, 17, e1009624.	4.7	2